Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention (PCSK9-DUO)
PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention
This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
Lowering low-density lipoprotein cholesterol (LDL-C) is essential to reduce the risk of cardiovascular events. While PCSK9 inhibitors are effective, many patients treated with a single agent do not reach recommended LDL-C targets, especially those who cannot take statins.
Inclisiran and alirocumab reduce LDL-C through different mechanisms. Inclisiran decreases the production of PCSK9 in the liver, while alirocumab binds circulating PCSK9 in the blood. Combining these therapies may lead to a greater reduction in LDL-C levels.
In this randomized, open-label clinical trial, approximately 60 patients in secondary prevention will be assigned to one of three groups: inclisiran alone, alirocumab alone, or a combination of both treatments. Patients will be followed for 9 months with regular clinical and laboratory assessments.
The main goal of the study is to determine whether combination therapy leads to greater LDL-C reduction compared to each treatment alone. Secondary objectives include assessing the proportion of patients achieving target LDL-C levels and evaluating treatment safety and tolerability.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a major modifiable risk factor. Despite the availability of effective lipid-lowering therapies, a substantial proportion of high-risk patients fail to achieve recommended LDL-C targets, particularly those with statin intolerance.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating LDL receptor degradation and plasma LDL-C levels. Pharmacological inhibition of PCSK9 has emerged as an effective strategy to reduce LDL-C. Two distinct therapeutic approaches are currently available: monoclonal antibodies (such as alirocumab), which neutralize circulating PCSK9, and small interfering RNA therapies (such as inclisiran), which reduce hepatic production of PCSK9.
Although both approaches have demonstrated efficacy, real-world data suggest that monotherapy may not be sufficient for many high-risk patients. The combination of these two mechanisms may provide additive or synergistic effects, leading to more profound LDL-C reduction.
This study is designed as a prospective, randomized, open-label, monocentric clinical trial. Approximately 60 adult patients in secondary prevention with statin intolerance and elevated LDL-C (2.5-5.0 mmol/L) will be enrolled. Participants will be randomized in a 1:1:1 ratio to receive inclisiran, alirocumab, or a combination of both therapies.
Inclisiran will be administered subcutaneously at baseline and at 3 months. Alirocumab will be administered subcutaneously at a dose of 300 mg every 4 weeks in a supervised clinical setting. Patients will be followed for 9 months, with study visits at baseline, 1 month, 3 months, 6 months, and 9 months.
The primary endpoint is the percentage change in LDL-C from baseline at 3 and 9 months. Secondary endpoints include the proportion of patients achieving guideline-recommended LDL-C targets, changes in other lipid parameters, and safety outcomes including adverse events and treatment tolerability.
This study aims to provide proof-of-concept evidence on the effectiveness and safety of dual PCSK9 inhibition using complementary mechanisms, with potential implications for improving lipid management in high-risk, statin-intolerant patients.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 4
Контакты и местонахождение
Контакты исследования
- Имя: Zlatko Fras, MD, PhD
- Номер телефона: +386 1 522 25 62
- Электронная почта: zlatko.fras@kclj.si
Учебное резервное копирование контактов
- Имя: Jan Kafol, MD
- Электронная почта: jan.kafol@kclj.si
Места учебы
-
-
-
Ljubljana, Словения, 1000
- Рекрутинг
- University Medical Centre Ljubljana
-
Контакт:
- Zlatko Fras, MD, PhD
- Номер телефона: +386 1 522 25 62
- Электронная почта: zlatko.fras@kclj.si
-
Контакт:
- Jan Kafol, MD
- Электронная почта: jan.kafol@kclj.si
-
Главный следователь:
- Jan Kafol, MD
-
Младший исследователь:
- Zlatko Fras, MD, PhD
-
Младший исследователь:
- Borut Jug, MD, PhD
-
Младший исследователь:
- Marko Novakovic, MD, PhD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Adults aged ≥18 years
- Established atherosclerotic cardiovascular disease (secondary prevention), defined as prior cardiovascular events or imaging-confirmed atherosclerosis (e.g., coronary artery disease on angiography or CT, carotid plaque on ultrasound, or peripheral arterial disease).
- Eligible for PCSK9 inhibitor therapy according to national clinical criteria
- Fasting LDL cholesterol ≥2.5 mmol/L and ≤5.0 mmol/L at screening
- Documented statin intolerance or contraindication to statin therapy
- On stable background lipid-lowering therapy (including ezetimibe if applicable) for at least 4 weeks prior to enrollment
- Able and willing to provide written informed consent
Exclusion Criteria:
- Eligibility for PCSK9 inhibitor therapy solely based on elevated lipoprotein(a) >1000 mg/L with LDL-C below inclusion threshold
- Prior use of any PCSK9 inhibitor (alirocumab, evolocumab or inclisiran) before enrollment
- Planned initiation or modification of lipid-lowering therapy during the study period
- Known homozygous familial hypercholesterolemia
- Active liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3× upper limit of normal
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Active malignancy or life expectancy <1 year
- Pregnancy, breastfeeding, or women of childbearing potential not using effective contraception
- Known hypersensitivity to inclisiran, alirocumab, or any of their excipients
- Participation in another interventional clinical trial within 30 days prior to enrollment
- Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Inclisiran
Participants receive inclisiran 284 mg administered subcutaneously at baseline and at 3 months.
Patients will be followed for 9 months with scheduled clinical and laboratory assessments.
|
Participants receive inclisiran 284 mg administered subcutaneously at baseline (Day 0) and at Month 3.
|
|
Экспериментальный: Alirocumab
Participants receive alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
Patients will be followed with regular clinical and laboratory assessments.
|
Participants receive alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
|
|
Экспериментальный: Inclisiran Plus Alirocumab
Participants receive inclisiran 284 mg administered subcutaneously at baseline and at 3 months, in combination with alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
Patients will be followed with scheduled clinical and laboratory assessments.
|
Participants receive inclisiran 284 mg administered subcutaneously at baseline (Day 0) and at Month 3.
Participants receive alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percent Change in LDL-C From Baseline
Временное ограничение: 3 months and 9 months
|
Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline at 3 months and 9 months, comparing inclisiran, alirocumab, and combination therapy.
|
3 months and 9 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Trajectory of Percent Change in LDL-C From Baseline
Временное ограничение: 1, 3, 6, and 9 months
|
Percent change in LDL-C from baseline at each scheduled follow-up visit to assess early response and durability of treatment effect.
|
1, 3, 6, and 9 months
|
|
Proportion of Participants Achieving LDL-C <1.4 mmol/L
Временное ограничение: 1, 3, 6, and 9 months
|
Proportion of participants achieving LDL-C below 1.4 mmol/L at each scheduled follow-up visit.
|
1, 3, 6, and 9 months
|
|
Change in Apolipoprotein B From Baseline
Временное ограничение: 1, 3, 6, and 9 months
|
Absolute and percent change in apolipoprotein B from baseline.
|
1, 3, 6, and 9 months
|
|
Change in Non-HDL Cholesterol From Baseline
Временное ограничение: 1, 3, 6, and 9 months
|
Absolute and percent change in non-HDL cholesterol from baseline.
|
1, 3, 6, and 9 months
|
|
Change in Lipoprotein(a) From Baseline
Временное ограничение: 1, 3, 6, and 9 months
|
Absolute and percent change in lipoprotein(a) from baseline.
|
1, 3, 6, and 9 months
|
|
Incidence of Adverse Events
Временное ограничение: Up to 9 months
|
Number and proportion of participants experiencing any adverse event during the study.
|
Up to 9 months
|
|
Treatment Discontinuation Due to Adverse Events
Временное ограничение: Up to 9 months
|
Proportion of participants who discontinue assigned study treatment because of adverse events.
|
Up to 9 months
|
|
Change in Circulating PCSK9 Concentration From Baseline
Временное ограничение: 1, 3, 6, and 9 months
|
Absolute and percent change in circulating PCSK9 concentration to assess pharmacodynamic effects of treatment.
|
1, 3, 6, and 9 months
|
|
Change From Baseline in LDL-C Concentration
Временное ограничение: 1, 3, 6, and 9 months
|
Absolute change in LDL-C concentration compared with baseline at each scheduled follow-up visit.
|
1, 3, 6, and 9 months
|
|
Change From Baseline in Total Cholesterol, HDL Cholesterol, and Triglyceride Concentrations
Временное ограничение: 1, 3, 6, and 9 months
|
Change in serum total cholesterol, HDL cholesterol, and triglyceride concentrations compared with baseline values.
|
1, 3, 6, and 9 months
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of Injection-Site Reactions
Временное ограничение: Up to 9 months
|
Number and proportion of participants experiencing injection-site reactions.
|
Up to 9 months
|
|
Treatment Adherence
Временное ограничение: Up to 9 months
|
Adherence to assigned therapy assessed by documented administration of inclisiran and alirocumab.
|
Up to 9 months
|
|
Major Adverse Cardiovascular Events
Временное ограничение: Up to 9 months
|
Exploratory assessment of cardiovascular death, myocardial infarction, stroke, urgent coronary revascularization, or hospitalization for unstable angina.
|
Up to 9 months
|
Соавторы и исследователи
Следователи
- Учебный стул: Zlatko Fras, MD, PhD, University Medical Centre Ljubljana
- Главный следователь: Jan Kafol, MD, University Medical Centre Ljubljana
Публикации и полезные ссылки
Общие публикации
- Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.
- Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available.
- Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B. Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. Lipids Health Dis. 2026 Mar 5;25(1):106. doi: 10.1186/s12944-026-02897-3.
- Mach F, Koskinas KC, Roeters van Lennep JE, Tokgozoglu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025 Nov 7;46(42):4359-4378. doi: 10.1093/eurheartj/ehaf190. No abstract available.
- Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- UKC-PCSK9-DUO
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Сроки обмена IPD
Критерии совместного доступа к IPD
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .